1.上海中医药大学附属曙光医院细胞生物学实验室(上海 201203)
2.上海市中医药研究院肝病研究所(上海 201203)
3.肝肾疾病病证教育部重点实验室(上海 201203)
4.上海市中医临床重点实验室(上海 201203)
战俊邑,男,博士研究生,主要从事中西医结合治疗肝硬化的基础与临床研究工作
刘成海,主任医师,教授,博士研究生导师;E-mail:chenghailiu@hotmail.com
慕永平,主任医师,博士研究生导师;E-mail:ypmu8888@126.com
扫 描 看 全 文
战俊邑,刘成海,慕永平.肝硬化门静脉高压症的中西医结合诊疗研究进展[J].上海中医药杂志,2023,57(8):11-15.
ZHAN Junyi,LIU Chenghai,MU Yongping.Advances in the diagnosis and treatment of cirrhotic portal hypertension with integrated traditional Chinese and Western medicine[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(8):11-15.
战俊邑,刘成海,慕永平.肝硬化门静脉高压症的中西医结合诊疗研究进展[J].上海中医药杂志,2023,57(8):11-15. DOI: 10.16305/j.1007-1334.2023.2303102.
ZHAN Junyi,LIU Chenghai,MU Yongping.Advances in the diagnosis and treatment of cirrhotic portal hypertension with integrated traditional Chinese and Western medicine[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(8):11-15. DOI: 10.16305/j.1007-1334.2023.2303102.
综述肝硬化门静脉高压症(CPHT)的中西医结合诊断和治疗研究进展。CPHT是肝硬化失代偿期以门静脉系统压力升高为主要病理特征,并继发包括食管-胃底静脉曲张、难治性腹水、肝性脑病等一系列症状的临床证候群。目前CPHT主要基于肝静脉压力梯度进行诊断和分级,但该法临床常规开展难度较大,因此各种无创诊断方法成为研究热点。该病的治疗目的为降低门静脉压力,预防和治疗各种严重并发症,治疗方案有解除病因、对症治疗、抗肝纤维化、减少门静脉血流、降低肝内阻力等,涉及药物、内镜、介入、外科等多种治疗手段。中医治疗CPHT的主要模式为病证结合,中西医结合疗法治疗本病具有一定的疗效优势,未来需进一步明确中西医结合的优势环节和作用机制,并形成规范化的中西医结合诊疗指南,以更好地指导临床实践。
This paper reviews the advances in the diagnosis and treatment of cirrhotic portal hypertension (CPHT) with integrated traditional Chinese and Western medicine (ITCWM). CPHT is a series of clinical syndromes in decompensated cirrhosis characterized by elevated pressure in the portal venous system, with secondary disorders such as esophagogastric varices, refractory ascites, and hepatic encephalopathy. Currently, CPHT is mainly diagnosed and graded based on the hepatic venous pressure gradient measurement, but it is difficult to be carried out routinely in clinical practice. Therefore, various non-invasive diagnostic methods have become a hot research topic. The aim of CPHT treatment is to reduce portal vein pressure, prevent and treat various serious complications. The treatment options include etiological treatment, symptomatic treatment, antihepatic fibrosis, reducing portal venous blood flow, and lowering intrahepatic resistance, etc., involving a variety of treatment methods such as drugs, endoscopy, intervention and surgery. The combined differentiation of disease and syndrome is the main pattern for the TCM treatment of CPHT, and the ITCWM has certain advantages in terms of efficacy. In the future, in order to better guide clinical practice, it is necessary to further clarify the competitive aspects and mechanism of action of the ITCWM, and to form standardized ITCWM treatment guidelines.
肝硬化门静脉高压症中西医结合临床诊疗病证结合
liver cirrhosisportal hypertensionintegrated traditional Chinese and Western medicineclinical diagnosis and treatmentdisease-syndrome combined differentiation
吕少诚,高沿航,王磊,等. 肝硬化门静脉高压症多学科诊治(基于肝静脉压力梯度)专家共识[J]. 临床肝胆病杂志,2021, 37(9): 2037-2044.
SIMONETTO D A, LIU M, KAMATH P S. Portal hypertension and related complications: diagnosis and management[J]. Mayo Clin Proc, 2019, 94(4): 714-726.
白志芹,宋会颖,吴瑞卿,等. 补气活血汤对乙型肝炎肝硬化门静脉高压患者血流动力学及肝纤维化指标的影响[J]. 临床肝胆病杂志,2017, 33(2): 272-276.
WANG T, ZHOU X L, LIU H H, et al. Fuzheng Huayu capsule as an adjuvant treatment for HBV-related cirrhosis: A systematic review and meta-analysis[J]. Phytother Res, 2018, 32(5): 757-768.
GRACIA-SANCHO J, MARRONE G, FERNÁNDEZ-IGLESIAS A. Hepatic microcirculation and mechanisms of portal hypertension[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 221-234.
BENOIT J N, WOMACK W A, HERNANDEZ L, et al. "Forward" and "backward" flow mechanisms of portal hypertension. Relative contributions in the rat model of portal vein stenosis[J]. Gastroenterology, 1985, 89(5): 1092-1096.
HUANG C T, DU R Y, LENG X S. Humoral mechanism in pathogenesis of portal hypertension[J]. Chin Med J, 1982, 95(6): 409-416.
慕永平,刘成海,张华,等. 肝硬化“虚损生积”论——刘平教授学术思想浅析[J]. 上海中医药大学学报,2013, 27(2): 1-4.
谭春雨,刘平. 肝硬化“虚损生积”病机理论溯源及其临床意义[J]. 上海中医药大学学报,2010, 24(4): 25-28.
邓鑫,文彬. 肝硬化门静脉高压症的中医病机特点分析[J]. 辽宁中医杂志,2012, 39(5): 816-818.
徐列明. 《肝纤维化中西医结合诊疗指南(2019年版)》解读[J]. 上海中医药杂志,2020, 54(3): 29-31, 52.
TURCO L, GARCIA-TSAO G. Portal hypertension: pathogenesis and diagnosis[J]. Clin Liver Dis, 2019, 23(4): 573-587.
LESMANA C R A, RAHARJO M, GANI R A. Managing liver cirrhotic complications: Overview of esophageal and gastric varices[J]. Clin Mol Hepatol, 2020, 26(4): 444-460.
DE FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974.
WANG J R, LU W X, LI J J, et al. Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: a meta-analysis[J]. Exp Ther Med, 2017, 13(5): 1977-1985.
HUET P M, VINCENT C, DESLAURIER J, et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment[J]. Gastroenterology, 2008, 135(5): 1552-1560.
VILLANUEVA C, TORRES F, SARIN S K, et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis[J]. J Hepatol, 2022, 77(4): 1014-1025.
GARBUZENKO D V. Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis[J]. World J Gastroenterol, 2015, 21(20): 6117-6126.
HUARINGA-MARCELO J, HUAMAN M R, BRAÑEZ-CONDORENA A, et al. Vasoactive agents for the management of acute variceal bleeding: a systematic review and meta-analysis[J]. J Gastrointestin Liver Dis, 2021, 30(1): 110-121.
GUNARATHNE L S, RAJAPAKSHA H, SHACKEL N, et al. Cirrhotic portal hypertension: from pathophysiology to novel therapeutics[J]. World J Gastroenterol, 2020, 26(40): 6111-6140.
WANG J, LU W, LI J, et al. Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis[J]. Exp Ther Med, 2017, 13(5): 1977-1985.
NETT A, BINMOELLER K F. Endoscopic management of portal hypertension-related bleeding[J]. Gastrointest Endosc Clin N Am, 2019, 29(2): 321-337.
OBARA K. Endoscopic treatment of esophagogastric varices[J]. Dig Endosc, 2022, 34(Suppl 2): 40-45.
TRIPATHI D, STANLEY A J, HAYES P C, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension[J]. Gut, 2020, 69(7): 1173-1192.
LV Y, ZUO L, ZHU X, et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study[J]. Gut, 2019, 68(7): 1297-1310.
KIM W R, LAKE J R, SMITH J M, et al. OPTN/SRTR 2016 Annual Data Report: Liver[J]. Am J Transplant, 2018, 18(Suppl 1): 172-253.
杜庆红,汤轶波,李卫红,等. 中药治疗肝硬化门静脉高压症的研究进展[J]. 世界中医药,2015, 10(7): 1120-1123.
张琴,刘平,章浩伟,等. 900例肝炎后肝硬化中医证候判别模式的研究[J]. 中国中西医结合杂志,2006, 26(8): 694-697.
张声生,王宪波,江宇泳. 肝硬化腹水中医诊疗专家共识意见(2017)[J]. 临床肝胆病杂志,2017, 33(9): 1621-1626.
慕永平. 肝硬化胃食管静脉曲张破裂出血的中西医结合诊疗进展[J]. 临床肝胆病杂志,2022, 38(9): 1962-1968.
陈冲,吕莹,陈茜蕾,等. 内镜结扎联合中医辨证论治对肝硬化食管静脉曲张破裂出血的二级预防效果[J]. 临床肝胆病杂志,2022, 38(5): 1075-1080.
孟宇航,李京涛,刘佳昊,等. 五苓散加减治疗肝硬化腹水的Meta分析[J]. 中医药导报,2020, 26(3): 43-46
佘为民,胡德昌,周朝晖,等. 肝平胶囊治疗慢性乙型肝炎患者肝纤维化的临床研究[J]. 肝脏,2002, 7(4): 254-255.
肖定洪,顾杰,蔡虹,等. 扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究[J]. 中华肝脏病杂志,2014, 22(8): 594-599.
段海珊,易俊秀,蒋黎,等. 超声造影评价鳖甲软肝片治疗乙肝肝硬化临床疗效[J]. 湖北中医药大学学报,2022, 24(3): 110-113.
石栓柱,陈翛然,古玉茹,等. 安络化纤丸联合恩替卡韦对乙型肝炎肝硬化患者门静脉系统血流动力学研究[J]. 中西医结合肝病杂志,2016, 26(6): 336-337, 373.
余学竟,赖国权,韦翠,等. 中医外治法对肝硬化腹水的Meta分析[J]. 辽宁中医杂志,2020, 47(11): 17-26.
许钰波. 针刺对肝硬化门静脉高压临床疗效研究[J]. 世界中医药,2017, 12(1): 152-156, 160.
何创,施维群,杨永和. “消臌贴膏”联合肝病治疗仪治疗肝硬化门脉高压疗效观察[J]. 中华中医药学刊,2016, 34(2): 499-502.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构